True North Labs

Author: labstruenorth@gmail.com

  • New Clinical Trial Launches to Compare Innovative Peptide-Drug Conjugate Against Standard Chemotherapy for Lung Cancer

    A new clinical trial has begun recruiting patients to study izalontamab brengitecan (also known as BMS-986507), an innovative antibody-drug conjugate therapy, as a potential option for people living with EGFR-mutated non-small cell lung cancer (NSCLC). The trial, named IZABRIGHT-Lung01, will compare this novel treatment approach against the current standard-of-care combination of platinum-based chemotherapy and pemetrexed in patients whose cancer has progressed despite prior treatment with EGFR tyrosine kinase inhibitors (TKIs).

    This represents an encouraging step forward for patients who face limited options after their EGFR-targeted therapy stops working. Izalontamab brengitecan combines a targeting antibody with a cytotoxic payload, allowing for a more precise delivery of cancer-fighting agents directly to tumor cells. This class of therapies, known as antibody-drug conjugates, has shown promise across multiple cancer types by potentially improving efficacy while aiming to spare healthy tissue from some of the broader effects associated with traditional chemotherapy.

    The initiation of this head-to-head trial against platinum-pemetrexed chemotherapy signals growing confidence in this therapeutic approach from researchers and sponsors. Comparative studies like this one are essential in determining whether newer treatments can offer meaningful improvements over existing standards of care, and the fact that this compound has progressed to this stage of testing reflects positive momentum in the broader effort to develop better therapies for EGFR-mutated lung cancer, a diagnosis that affects a significant number of NSCLC patients worldwide.

    For the lung cancer community, every new well-designed clinical trial represents hope and progress. Patients who have exhausted first-line EGFR TKI options often face a challenging treatment landscape, and trials like IZABRIGHT-Lung01 aim to expand the toolkit available to oncologists and patients alike. As this study progresses, it will contribute valuable data to the scientific understanding of how antibody-drug conjugates may fit into the treatment sequence for this specific lung cancer subtype.

    Developments like this highlight the continued innovation happening within oncology research, particularly in the peptide and antibody-conjugate space, where precision-targeted approaches are increasingly being explored as alternatives or complements to traditional chemotherapy regimens. This is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  • New Clinical Trial Launches to Explore Investigational Peptide-Based Therapy ABBV-901 for Ovarian Cancer

    New Clinical Trial Launches to Explore Investigational Peptide-Based Therapy ABBV-901 for Ovarian Cancer

    A new international clinical trial has begun recruiting participants to study ABBV-901, an investigational therapy being developed for the treatment of ovarian cancer. The study, registered on ClinicalTrials.gov, represents a meaningful step forward in the search for new treatment options for this challenging disease.

    The trial is notably comprehensive in scope, featuring six distinct study parts designed to carefully evaluate ABBV-901 both as a standalone treatment and in combination with other anticancer therapies, including bevacizumab and carboplatin. This structured, phased approach allows researchers to methodically assess dosing, safety, and how the body processes the drug before moving into larger combination therapy phases. Approximately 285 participants are expected to enroll across roughly 45 sites worldwide, reflecting a substantial global effort to generate robust data.

    What makes this trial particularly encouraging is its combination-therapy design. Rather than testing ABBV-901 in isolation, researchers are also exploring how it may work alongside already-established treatments like bevacizumab and carboplatin, which are familiar components of ovarian cancer care. This approach could potentially help identify synergistic treatment strategies that build on existing standards of care rather than starting from scratch.

    Ovarian cancer remains a serious health challenge, and the launch of new investigational studies like this one reflects the ongoing commitment within the research community to develop better tools for patients and clinicians. Trials of this nature—spanning dose escalation, optimization, and expansion phases—are foundational to bringing potential new therapies through the rigorous evaluation process required before they can become part of standard care.

    While the study will require meaningful participation from volunteers, including regular visits, blood tests, and imaging, such thorough monitoring is a hallmark of responsible clinical research aimed at protecting participant safety while generating the data needed to understand a new therapy’s potential. The three-year study duration will allow researchers time to gather meaningful insights into both safety and efficacy outcomes.

    This is an early-stage investigational trial, and it will be some time before results are available. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

  • New Pilot Trial to Explore Oral Vancomycin for Ulcerative Colitis Patients with Liver Condition PSC

    New Pilot Trial to Explore Oral Vancomycin for Ulcerative Colitis Patients with Liver Condition PSC

    A newly launched clinical trial is set to examine whether oral vancomycin, a well-known glycopeptide antibiotic, could offer a new treatment option for people living with both ulcerative colitis (UC) and primary sclerosing cholangitis (PSC), a rare liver condition that frequently accompanies inflammatory bowel disease. The study, registered on ClinicalTrials.gov, represents an encouraging step toward better understanding how targeted antibiotic therapy might help this specific and often under-studied patient population.

    The trial will enroll adult participants who have active UC alongside PSC, randomly assigning them to receive either oral vancomycin (250 mg twice daily) or a matching placebo for four weeks. Those who complete the initial phase will have the option to continue with an additional four weeks of open-label vancomycin, allowing researchers to gather more insight into longer-term tolerability. Throughout the study, participants will undergo regular clinic visits that include Mayo score assessments, endoscopy, and blood and stool testing to monitor both UC activity and liver health.

    What makes this study particularly promising is its thoughtful, feasibility-focused design. Rather than jumping straight to large-scale efficacy claims, the researchers are first asking foundational questions: Can enough participants be recruited and retained? Will adherence to the treatment protocol be strong? These are essential building blocks for any future, larger trial, and a well-run pilot study like this one helps ensure that subsequent research is built on a solid foundation.

    Beyond feasibility, the trial will also collect valuable secondary data on safety, early signs of improvement in UC symptoms, liver function markers, and shifts in gut bacterial balance. Since PSC and UC often occur together and can be challenging to manage simultaneously, any research that explores treatments addressing both conditions is a welcome development. Oral vancomycin is already used in clinical settings for certain gastrointestinal infections, so examining its potential role in this dual-diagnosis population builds on existing, familiar ground rather than starting from scratch.

    While results are still to come, the initiation of this trial reflects the kind of methodical, patient-centered research that can eventually lead to improved treatment pathways for people managing these intertwined conditions. True North Labs will continue to follow this study as it progresses and share updates on what researchers learn.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on any treatment or clinical trial participation.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

  • New Phase 3 Trial Launches for Oral VK2735 in Weight Management for Adults with Type 2 Diabetes

    New Phase 3 Trial Launches for Oral VK2735 in Weight Management for Adults with Type 2 Diabetes

    Exciting news is unfolding in the world of peptide-based therapeutics: a new Phase 3 clinical trial, known as SUNRISE 2, has been launched to study oral VK2735 for weight management in adults living with Type 2 Diabetes Mellitus. This trial specifically targets individuals who are classified as overweight (BMI ≥ 27 kg/m2) or obese (BMI ≥ 30 kg/m2), representing a significant population that often faces complex challenges in managing both blood sugar and body weight simultaneously.

    SUNRISE 2 is one of two planned Phase 3 studies designed to support a potential weight management indication for oral VK2735. The advancement to Phase 3 status is a meaningful milestone in drug development, as it typically follows encouraging results from earlier-phase studies and signals that researchers and regulators see strong enough promise to warrant larger, more definitive trials involving broader patient groups.

    What makes this development particularly noteworthy is the oral formulation of VK2735. Many current peptide-based weight management and metabolic therapies require injection, so an effective oral option could offer a more convenient and accessible alternative for patients. For individuals managing Type 2 Diabetes alongside weight concerns, having additional treatment formats to discuss with their healthcare providers may help support more personalized and sustainable approaches to care.

    The focus on this dual population—those with both elevated body weight and Type 2 Diabetes—reflects a growing recognition in the medical community of how interconnected these health factors can be. Trials like SUNRISE 2 contribute valuable data that may eventually help inform treatment guidelines and expand the toolkit available to clinicians and patients alike. As this study progresses, it adds to the broader momentum within peptide research aimed at addressing metabolic health challenges.

    We’ll continue to follow the progress of SUNRISE 2 and related studies as they move through the clinical trial process. This article is for informational purposes only and is not intended as medical advice; individuals should consult their healthcare provider for guidance specific to their health needs.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

  • New Clinical Trial Explores Peptide Hormones to Protect Heart Health in People with HIV

    New Clinical Trial Explores Peptide Hormones to Protect Heart Health in People with HIV

    People living with HIV, even those whose infection is well-controlled with modern antiretroviral therapy, face a higher risk of cardiovascular disease compared to the general population. A newly registered clinical trial, known as the ENCHANTMENT HIV Study, is taking aim at this challenge by examining the role of two important hormones: aldosterone and brain natriuretic peptide (BNP).

    Both aldosterone and BNP play key roles in regulating blood pressure, fluid balance, and heart function. Prior research has shown that these hormones can become dysregulated in people with HIV, potentially contributing to inflammation and early structural changes in the heart. By studying therapies designed to block aldosterone activity while supporting healthy BNP levels, researchers hope to better understand how these hormonal pathways influence cardiovascular health in this population.

    The goal of the ENCHANTMENT HIV Study is to determine whether this combined hormonal approach can help reduce the burden of heart-related complications and potentially slow the progression toward heart failure. This represents a proactive and targeted strategy, moving beyond general cardiovascular risk management to address specific biological mechanisms that may be unique to people living with HIV.

    What makes this research especially encouraging is its focus on prevention and early intervention. Rather than waiting for cardiovascular disease to become advanced, the study is designed to catch and address subtle changes in heart structure and function before they progress. If successful, this approach could pave the way for new, more personalized cardiovascular care strategies tailored to the needs of people living with HIV.

    As the trial progresses, it adds to a growing body of research exploring how peptide hormones like BNP can be leveraged not just as diagnostic markers, but as potential therapeutic targets. Studies like this highlight the ongoing commitment within the medical research community to improve long-term health outcomes for people with HIV, extending the focus of care beyond viral suppression to overall well-being and longevity.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: The ENCHANTMENT HIV Study

  • New Clinical Trial Explores Blood Biomarkers to Protect the Heart During Lung Cancer Radiation Therapy

    New Clinical Trial Explores Blood Biomarkers to Protect the Heart During Lung Cancer Radiation Therapy

    A newly launched clinical trial is investigating a promising approach to safeguarding heart health in patients undergoing radiation therapy for non-small cell lung cancer. Researchers will track two blood-based biomarkers, Pro-N-Cadherin and NT-proBNP, a well-studied peptide hormone linked to heart function, to see whether early changes in these markers can signal a patient’s risk of developing radiation-related heart problems.

    Hypofractionated radiation therapy, a treatment that delivers higher doses over fewer sessions, has become an important option for many lung cancer patients because it can be more convenient and efficient. However, because the heart sits close to the lungs, radiation exposure to cardiac tissue is an ongoing concern for oncologists. This trial aims to give doctors a clearer, more proactive way to monitor that risk in real time.

    Over a two-year follow-up period, participants will undergo routine blood collection and echocardiography, allowing researchers to compare biomarker levels against actual radiation dose to the heart and any resulting cardiac dysfunction or adverse events. The ultimate goal is to determine whether simple blood tests could one day help clinicians identify at-risk patients earlier, potentially allowing for adjusted treatment plans or closer cardiac monitoring before serious complications develop.

    What makes this research particularly encouraging is its focus on prevention and personalization. If Pro-N-Cadherin and NT-proBNP prove to be reliable early indicators, oncologists could gain a valuable, minimally invasive tool to tailor radiation therapy more safely for individual patients. This kind of biomarker-driven approach reflects a broader, positive trend in cancer care: using precise, measurable biological signals to reduce treatment side effects while preserving the effectiveness of life-saving therapies.

    As the trial progresses, its findings could contribute meaningfully to safer cancer treatment protocols and improved quality of life for patients navigating both cancer and cardiovascular health. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients

  • FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management

    FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management

    Peptide-based therapies have become one of the most talked-about advances in weight management in recent years, with several formulations receiving FDA approval for use in appropriate clinical settings. These medications, which work by mimicking natural hormones involved in appetite regulation and metabolism, represent a significant shift in how obesity and weight-related health concerns can be addressed through pharmacological support.

    The growing acceptance of peptide-based treatments by regulatory bodies reflects a broader recognition within the medical community that obesity is a complex, multifactorial condition that can benefit from targeted therapeutic interventions. Unlike earlier generations of weight-loss drugs, many of today’s peptide therapies are designed to work in harmony with the body’s own signaling pathways, which may contribute to their improved safety profiles and tolerability when used under proper medical guidance.

    For patients and healthcare providers, FDA approval status is an important marker of confidence, since it typically follows extensive review of clinical data demonstrating both efficacy and an acceptable safety profile. This kind of regulatory green light can also help expand insurance coverage and accessibility, making these treatment options available to a wider range of patients who may benefit from medically supervised weight management programs.

    The continued interest in peptide science also fuels further research and innovation, as pharmaceutical companies and academic researchers explore new formulations, delivery methods, and combination therapies. This ongoing investment suggests that patients may see even more refined and effective options emerge in the coming years, building on the foundation laid by currently approved treatments.

    As with any medical treatment, decisions about weight management therapies should be made in consultation with a qualified healthcare provider who can evaluate individual health needs and circumstances. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: fda approved peptides for weight loss – www.polskieradio.pl

  • FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management

    FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management

    Peptide-based therapies have become an increasingly important part of the FDA-approved toolkit for weight management. Over the past few years, the agency has granted approval to several injectable peptide medications, including GLP-1 receptor agonists, specifically for chronic weight management in adults with obesity or who are overweight with related health conditions. These approvals mark a significant step in bringing peptide science from the laboratory into mainstream clinical care.

    These medications work by mimicking naturally occurring gut hormones that help regulate appetite and blood sugar levels. Because they are peptides—short chains of amino acids similar to proteins the body already produces—they can interact with existing biological pathways in ways that many patients and physicians find to be a well-tolerated approach compared to some older weight management drugs. Clinical trials supporting these approvals showed meaningful average weight reduction among participants, which contributed to the FDA’s decision to greenlight their use under medical supervision.

    The expanding approval landscape reflects growing confidence from regulators in the peptide drug class as a whole. As more of these therapies move through the FDA pipeline, patients gain access to a broader range of options, allowing doctors to tailor treatment plans based on individual health profiles, lifestyle, and goals. This growing menu of approved choices is also spurring further investment in peptide research, as pharmaceutical companies look to refine dosing, improve convenience, and explore additional applications.

    For the broader peptide field, FDA approval of weight management treatments serves as an encouraging signal. It demonstrates that rigorously tested peptide therapies can successfully navigate the regulatory process and reach patients who may benefit from them. It also underscores the importance of obtaining peptide treatments through legitimate, regulated channels—such as licensed pharmacies and healthcare providers—rather than unverified sources, ensuring that patients receive products that have been properly studied for safety and effectiveness.

    As research continues and new peptide candidates move through clinical trials, the weight management category is likely to see further innovation in the years ahead. This progress highlights how peptide science is translating into real, regulated treatment options that support patients working alongside their healthcare teams.

    This article is for informational purposes only and is not medical advice. Please consult a qualified healthcare provider before starting any new treatment.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: fda approved peptides for weight loss – www.polskieradio.pl

  • New Clinical Framework Supports Safely Reducing Insulin Use with GLP-1 Therapy in Type 2 Diabetes

    New Clinical Framework Supports Safely Reducing Insulin Use with GLP-1 Therapy in Type 2 Diabetes

    A new publication in the peer-reviewed journal Cureus offers encouraging news for people managing type 2 diabetes: a practical, evidence-based framework for reducing insulin use in patients who are also taking GLP-1 (glucagon-like peptide-1) receptor agonist medications. This development reflects a broader and welcome shift in diabetes care toward simplifying treatment regimens when appropriate, without compromising blood sugar control.

    GLP-1-based therapies have already transformed the diabetes treatment landscape by helping patients improve glycemic control, often while supporting weight management. For many patients on combination therapy with insulin, this raises an important clinical question: once GLP-1 therapy is established and working well, can insulin doses be safely reduced or even discontinued? The new framework synthesizes existing evidence to help clinicians answer this question with greater confidence and consistency.

    The significance of this work lies in its practical, patient-centered approach. Insulin therapy, while effective, carries burdens for patients including the risk of low blood sugar episodes, weight gain, and the day-to-day complexity of injections and dose adjustments. By offering clinicians clear criteria and a structured process for considering insulin deintensification, this framework could help more patients transition toward simpler, more manageable treatment plans when their clinical picture supports it.

    This kind of synthesis work is valuable because it translates scattered research findings into an actionable tool that healthcare providers can use in everyday practice. Rather than leaving decisions about combining or adjusting GLP-1 and insulin therapies to guesswork, clinicians now have a reference point grounded in available evidence. For patients, this could mean more personalized care that takes into account their individual response to GLP-1 therapy and their broader treatment goals.

    As GLP-1 medications continue to expand in availability and use, frameworks like this one help ensure that the full potential of these therapies is realized safely and effectively. Streamlining diabetes regimens where clinically appropriate can reduce treatment burden and support better long-term adherence and outcomes. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework – Cureus

  • New Comparative Trial Explores Metformin and Insulin Options for Gestational Diabetes Care

    New Comparative Trial Explores Metformin and Insulin Options for Gestational Diabetes Care

    A new comparative-effectiveness clinical trial, known as DECIDE, is underway to help expand treatment options for individuals diagnosed with gestational diabetes mellitus (GDM). The study will enroll 1,572 pregnant participants across 20 sites in the United States, comparing the effectiveness and safety of oral metformin against injectable insulin—the current standard treatment—for managing blood sugar levels during pregnancy.

    Insulin, a naturally occurring peptide hormone, has long been the primary pharmacological treatment for GDM when lifestyle changes alone aren’t enough to manage blood sugar. However, insulin requires injections, which can be a barrier for some patients. Metformin, an oral medication, has grown in use as an alternative, but more robust, large-scale evidence is needed to confirm whether it performs comparably to insulin in protecting both parent and child health outcomes.

    What makes this trial especially encouraging is its patient-centered design. Beyond measuring clinical outcomes like pregnancy complications, researchers will also track patient-reported experiences—identifying what makes a treatment easier or harder to follow. This kind of real-world insight can help clinicians tailor care recommendations based on what actually works best for patients’ daily lives, not just lab results.

    The study’s extended follow-up period, tracking both parents and children for two years postpartum, is also a notable strength. This long-term view will help build a fuller picture of safety and developmental outcomes, giving future parents and their doctors more confidence when making treatment decisions. If metformin proves to be non-inferior to insulin, it could offer a more convenient, non-injectable option for many pregnant individuals managing GDM—potentially easing treatment burden without compromising safety.

    Trials like DECIDE reflect the ongoing effort to refine and personalize care for pregnancy-related conditions, ensuring that both established peptide-based treatments like insulin and emerging oral alternatives are rigorously evaluated. As more comparative data becomes available, patients and providers alike stand to benefit from clearer, evidence-based guidance. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes